Total Payments
$422,982
2024 Payments
$117,713
Companies
46
Transactions
1,432
Medicare Patients
4,625
Medicare Billing
$1.6M
Payment Breakdown by Category
Other$317,085 (75.0%)
Consulting$50,780 (12.0%)
Travel$30,956 (7.3%)
Food & Beverage$24,131 (5.7%)
Education$29.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $317,085 | 243 | 75.0% |
| Consulting Fee | $50,780 | 24 | 12.0% |
| Travel and Lodging | $30,956 | 224 | 7.3% |
| Food and Beverage | $24,131 | 940 | 5.7% |
| Education | $29.99 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Avanir Pharmaceuticals, Inc. | $122,428 | 240 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $67,730 | 160 | $0 (2024) |
| Eisai Inc. | $53,283 | 138 | $0 (2024) |
| Axsome Therapeutics, Inc. | $49,558 | 72 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $45,825 | 125 | $0 (2024) |
| IDORSIA PHARMACEUTICALS US INC | $31,809 | 72 | $0 (2024) |
| Takeda Pharmaceuticals America, Inc. | $15,061 | 36 | $0 (2017) |
| Allergan, Inc. | $10,339 | 72 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $9,306 | 104 | $0 (2024) |
| Alkermes, Inc. | $7,538 | 25 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $117,713 | 300 | Otsuka America Pharmaceutical, Inc. ($40,621) |
| 2023 | $62,513 | 221 | Otsuka America Pharmaceutical, Inc. ($21,430) |
| 2022 | $32,736 | 194 | Avanir Pharmaceuticals, Inc. ($15,200) |
| 2021 | $34,887 | 211 | Eisai Inc. ($13,265) |
| 2020 | $41,400 | 108 | Eisai Inc. ($38,334) |
| 2019 | $42,892 | 140 | Avanir Pharmaceuticals, Inc. ($30,498) |
| 2018 | $57,207 | 140 | Avanir Pharmaceuticals, Inc. ($52,360) |
| 2017 | $33,634 | 118 | Avanir Pharmaceuticals, Inc. ($17,110) |
All Payment Transactions
1,432 individual payment records from CMS Open Payments — Page 1 of 58
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,078.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/21/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $125.60 | General |
| Category: PSYCHIATRY | ||||||
| 12/21/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $110.10 | General |
| Category: PSYCHIATRY | ||||||
| 12/20/2024 | Noven Therapeutics, LLC | Xelstrym (Drug) | Food and Beverage | In-kind items and services | $20.14 | General |
| Category: ADHD | ||||||
| 12/19/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $7.38 | General |
| Category: Neuroscience | ||||||
| 12/17/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: ANTI-ANXIETY | ||||||
| 12/14/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $2.52 | General |
| Category: Neuropsychiatry | ||||||
| 12/13/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $30.82 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,564.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/12/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $71.37 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $63.69 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $47.17 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $42.62 | General |
| Category: PSYCHIATRY | ||||||
| 12/10/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $152.52 | General |
| Category: PSYCHIATRY | ||||||
| 12/10/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: Neuroscience | ||||||
| 12/05/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $22.01 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | In-kind items and services | $1,022.95 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $68.95 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $12.62 | General |
| Category: NEUROSCIENCE | ||||||
| 12/03/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $7.61 | General |
| Category: Insomnia | ||||||
| 11/27/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $595.00 | General |
| Category: Insomnia | ||||||
| 11/27/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | In-kind items and services | $213.11 | General |
| Category: PSYCHIATRY | ||||||
| 11/25/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,550.00 | General |
| Category: Insomnia | ||||||
| 11/25/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Travel and Lodging | In-kind items and services | $333.29 | General |
| Category: Insomnia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 986 | 4,086 | $1.3M | $326,315 |
| 2022 | 17 | 951 | 3,721 | $1.1M | $304,112 |
| 2021 | 20 | 1,166 | 4,597 | $1.4M | $431,144 |
| 2020 | 13 | 1,522 | 6,321 | $2.0M | $571,634 |
Total Patients
4,625
Total Services
18,725
Medicare Billing
$1.6M
Procedure Codes
64
All Medicare Procedures & Services
64 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2023 | 48 | 1,387 | $762,052 | $192,322 | 25.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 257 | 1,107 | $332,000 | $79,863 | 24.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 61 | 151 | $30,200 | $13,482 | 44.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 110 | 209 | $42,009 | $10,269 | 24.4% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 24 | 24 | $36,000 | $6,852 | 19.0% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 46 | 48 | $16,800 | $6,504 | 38.7% |
| 90867 | Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | Office | 2023 | 38 | 39 | $27,312 | $5,651 | 20.7% |
| 95957 | Measurement of brain wave activity (eeg), digital analysis | Office | 2023 | 24 | 24 | $36,000 | $5,028 | 14.0% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2023 | 247 | 954 | $23,851 | $3,141 | 13.2% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 36 | 44 | $5,975 | $1,475 | 24.7% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 25 | 27 | $2,896 | $686.88 | 23.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 31 | 31 | $4,650 | $624.15 | 13.4% |
| 93040 | Electrocardiogram (ecg) 1 to 3 leads with review by physician | Office | 2023 | 24 | 24 | $1,200 | $232.56 | 19.4% |
| 90785 | Psychiatric services complicated by communication factor | Office | 2023 | 15 | 17 | $850.00 | $185.34 | 21.8% |
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2022 | 30 | 974 | $487,000 | $135,558 | 27.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 215 | 959 | $287,811 | $82,822 | 28.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 105 | 355 | $53,250 | $22,555 | 42.4% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 72 | 273 | $40,450 | $13,794 | 34.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 103 | 216 | $43,215 | $13,119 | 30.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 35 | 111 | $22,200 | $10,075 | 45.4% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 24 | 24 | $36,000 | $7,099 | 19.7% |
| 95957 | Measurement of brain wave activity (eeg), digital analysis | Office | 2022 | 24 | 24 | $36,000 | $4,862 | 13.5% |
| 90867 | Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | Office | 2022 | 26 | 30 | $15,000 | $4,291 | 28.6% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 30 | 30 | $10,500 | $4,105 | 39.1% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2022 | 192 | 627 | $15,885 | $2,075 | 13.1% |
About Dr. David Crumpacker, MD
Dr. David Crumpacker, MD is a Psychiatry healthcare provider based in Plano, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2005. The National Provider Identifier (NPI) number assigned to this provider is 1912996562.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Crumpacker, MD has received a total of $422,982 in payments from pharmaceutical and medical device companies, with $117,713 received in 2024. These payments were reported across 1,432 transactions from 46 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($317,085).
As a Medicare-enrolled provider, Crumpacker has provided services to 4,625 Medicare beneficiaries, totaling 18,725 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 64 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Plano, TX
- Active Since 10/17/2005
- Last Updated 02/02/2024
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1912996562
Products in Payments
- NUEDEXTA (Drug) $135,865
- REXULTI (Drug) $53,865
- Dayvigo (Drug) $53,187
- Auvelity (Drug) $49,466
- SPRAVATO (Drug) $45,803
- QUVIVIQ (Drug) $31,809
- Trintellix (Drug) $23,562
- VRAYLAR (Drug) $11,273
- LYBALVI (Drug) $7,089
- AUSTEDO (Drug) $2,968
- Nuedexta (Drug) $1,037
- Equetro (Drug) $923.72
- TRINTELLIX (Drug) $656.93
- LATUDA (Drug) $571.56
- INGREZZA (Drug) $330.73
- HETLIOZ (Drug) $327.21
- ARISTADA (Drug) $298.70
- CAPLYTA (Drug) $262.44
- ABILIFY MAINTENA (Drug) $228.05
- Dyanavel XR (Drug) $222.35
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Plano
Suresh Sureddi, M.d, M.D
Psychiatry — Payments: $2.3M
Psychiatry $2.3M
Dr. Ronald Moomaw, D.o, D.O
Psychiatry — Payments: $113,022
Psychiatry $113,022
Dante Burgos, M.d, M.D
Psychiatry — Payments: $11,168
Psychiatry $11,168
Robert Benigar Jr, Md, MD
Psychiatry — Payments: $9,749
Psychiatry $9,749
Dr. Dan Steinfink, Md, MD
Psychiatry — Payments: $8,786
Psychiatry $8,786
Dr. Mohammad Khan, Md, MD
Psychiatry — Payments: $6,195
Psychiatry $6,195